AP3337A - Aminoalcohol substituted 2,3-dihydroimidazo[1,2-C]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis - Google Patents

Aminoalcohol substituted 2,3-dihydroimidazo[1,2-C]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis

Info

Publication number
AP3337A
AP3337A AP2013006921A AP2013006921A AP3337A AP 3337 A AP3337 A AP 3337A AP 2013006921 A AP2013006921 A AP 2013006921A AP 2013006921 A AP2013006921 A AP 2013006921A AP 3337 A AP3337 A AP 3337A
Authority
AP
ARIPO
Prior art keywords
dihydroimidazo
angiogenesis
diseases associated
proliferative disorders
derivatives useful
Prior art date
Application number
AP2013006921A
Other languages
English (en)
Other versions
AP2013006921A0 (en
Inventor
William Johnston Scott
Ursula Mönning
Andrea Hägebarth
Original Assignee
Bayer Intellectual Property
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44999756&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP3337(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Intellectual Property filed Critical Bayer Intellectual Property
Publication of AP2013006921A0 publication Critical patent/AP2013006921A0/xx
Application granted granted Critical
Publication of AP3337A publication Critical patent/AP3337A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AP2013006921A 2010-11-11 2011-11-08 Aminoalcohol substituted 2,3-dihydroimidazo[1,2-C]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis AP3337A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41255610P 2010-11-11 2010-11-11
PCT/EP2011/069637 WO2012062748A1 (en) 2010-11-11 2011-11-08 Aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis

Publications (2)

Publication Number Publication Date
AP2013006921A0 AP2013006921A0 (en) 2013-06-30
AP3337A true AP3337A (en) 2015-07-31

Family

ID=44999756

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2013006921A AP3337A (en) 2010-11-11 2011-11-08 Aminoalcohol substituted 2,3-dihydroimidazo[1,2-C]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis

Country Status (31)

Country Link
US (2) US8895549B2 (es)
EP (1) EP2638045B1 (es)
JP (1) JP6196156B2 (es)
KR (1) KR20140003436A (es)
CN (1) CN102906094B (es)
AP (1) AP3337A (es)
AR (1) AR083842A1 (es)
AU (1) AU2011328192B2 (es)
BR (1) BR112013011634A2 (es)
CA (1) CA2817317C (es)
CL (1) CL2013001295A1 (es)
CO (1) CO6761350A2 (es)
CR (1) CR20130213A (es)
CU (1) CU20130069A7 (es)
DO (1) DOP2013000105A (es)
EA (1) EA024406B1 (es)
EC (1) ECSP13012618A (es)
GT (1) GT201300121A (es)
HK (1) HK1180685A1 (es)
IL (1) IL226066A0 (es)
MA (1) MA34655B1 (es)
MX (1) MX2013005305A (es)
MY (1) MY164730A (es)
NZ (1) NZ610018A (es)
PE (1) PE20140411A1 (es)
SG (1) SG190100A1 (es)
TW (1) TW201305170A (es)
UA (1) UA113280C2 (es)
UY (1) UY33719A (es)
WO (1) WO2012062748A1 (es)
ZA (1) ZA201304244B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA113280C2 (xx) * 2010-11-11 2017-01-10 АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ
EP2638043B1 (en) * 2010-11-11 2017-06-07 Bayer Intellectual Property GmbH Arylaminoalcohol-substituted 2,3-dihydroimidazo[1,2-c]quinolines
CA2817312A1 (en) * 2010-11-11 2012-05-18 Bayer Intellectual Property Gmbh Alkoxy-substituted 2,3-dihydroimidazo[1,2-c]quinazolines
JO3733B1 (ar) 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
CN103214489B (zh) * 2013-02-25 2016-10-26 中国人民解放军第二军医大学 一类具有抗肿瘤活性的多靶点激酶抑制剂及其制备方法
JP6368353B2 (ja) * 2013-04-08 2018-08-01 バイエル ファーマ アクチエンゲゼルシャフト 置換された２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリン類のリンパ腫治療への使用
JP6499657B2 (ja) 2013-12-03 2019-04-10 バイエル ファーマ アクチエンゲゼルシャフト Ｐｉ３ｋ阻害剤の組み合わせ
EP3077003A1 (en) 2013-12-03 2016-10-12 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors
WO2015082376A2 (en) 2013-12-03 2015-06-11 Bayer Pharma Aktiengesellschaft Use of pi3k-inhibitors
WO2016071382A1 (en) * 2014-11-07 2016-05-12 Bayer Pharma Aktiengesellschaft Synthesis of pi3k inhibitor and salts thereof
WO2016071380A1 (en) * 2014-11-07 2016-05-12 Bayer Pharma Aktiengesellschaft Synthesis of pi3k inhibitor and salts thereof
WO2016087488A1 (en) * 2014-12-03 2016-06-09 Bayer Pharma Aktiengesellschaft Administration regime for aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives
WO2016087490A1 (en) * 2014-12-03 2016-06-09 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors
KR20180104597A (ko) 2015-11-07 2018-09-21 멀티비르 인코포레이티드 암 치료를 위한 종양 억제 유전자 요법 및 면역관문 봉쇄를 포함하는 조성물
CA3037626A1 (en) 2016-09-23 2018-03-29 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors
JP2020510624A (ja) 2016-12-12 2020-04-09 マルチビア インコーポレイテッド がんおよび感染性疾患の治療および予防のための、ウイルス遺伝子治療および免疫チェックポイント阻害剤を含む方法および組成物
WO2018215282A1 (en) 2017-05-26 2018-11-29 Bayer Pharma Aktiengesellschaft Combination of bub1 and pi3k inhibitors
US11185549B2 (en) 2017-06-28 2021-11-30 Bayer Consumer Care Ag Combination of a PI3K-inhibitor with an androgen receptor antagonist
CA3094329A1 (en) 2018-03-19 2020-02-20 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer
CN108383849B (zh) * 2018-04-26 2020-11-06 浙江大学 咪唑并喹唑啉衍生物及其在抗肿瘤抗炎中的应用
US20230029385A1 (en) * 2019-10-15 2023-01-26 Bayer Aktiengesellschaft 2-methyl-aza-quinazolines
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
WO2021260443A1 (en) 2020-06-24 2021-12-30 Bayer Aktiengesellschaft Combinations of 2,3-dihydroimidazo[1,2-c]quinazolines
CN115572256A (zh) * 2021-06-21 2023-01-06 武汉睿健医药科技有限公司 Oct4高选择性活化剂
CN113512040B (zh) * 2021-08-25 2023-10-13 河南牧业经济学院 一种血根碱仿生化合物及其制备方法
TW202404968A (zh) * 2022-04-20 2024-02-01 美商思諾維新醫藥公司 ＰＩ３Ｋα抑制劑
WO2023230262A1 (en) * 2022-05-26 2023-11-30 Synnovation Therapeutics, Inc. Tricyclic compounds as pi3kalpha inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004029055A1 (en) * 2002-09-30 2004-04-08 Bayer Pharmaceuticals Corporation Fused azole-pyrimidine derivatives
WO2008070150A1 (en) * 2006-12-05 2008-06-12 Bayer Schering Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2010034414A1 (en) * 2008-09-24 2010-04-01 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
GB9400680D0 (en) 1994-01-14 1994-03-09 Sandoz Ltd Improvements in or relating to organic compounds
US5792766A (en) 1996-03-13 1998-08-11 Neurogen Corporation Imidazo 1,5-c! quinazolines; a new class of GABA brain receptor ligands
CN1882569B (zh) 2003-09-19 2010-09-29 阿斯利康(瑞典)有限公司 喹唑啉衍生物
US8871782B2 (en) * 2003-10-03 2014-10-28 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
JPWO2005080392A1 (ja) * 2004-02-19 2007-08-02 武田薬品工業株式会社 ピラゾロキノロン誘導体およびその用途
PT2066653E (pt) 2006-08-03 2012-10-22 Rottapharm Spa Derivados de 6-1h-imidazo-quinazolina e quinolinas, novos potentes analgésicos e agentes anti-inflamatórios
GB2454549B (en) * 2007-09-25 2009-09-23 Medical & Pharm Ind Tech & Dev Uses of 2-[piperidinyl]methyl-2,3-dihydroimidazo[1,2-c]quinazolin-5(6H)-one for providing an anti-allergic effect and histamine H1 receptor antagonism effect
WO2009152868A1 (en) 2008-06-20 2009-12-23 Rottapharm S.P.A. 6-1h-imidazo-quinazoline and quinolines derivatives, new mao inhibitors and imidazoline receptor ligands
JP5542133B2 (ja) 2008-06-26 2014-07-09 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ ピラゾロ−キナゾリン
MA34158B1 (fr) 2010-04-16 2013-04-03 Bayer Ip Gmbh Combinaisons contenant une 2,3-dihydroimidazo{1,2-c]quinazoline substituée
EP2638043B1 (en) * 2010-11-11 2017-06-07 Bayer Intellectual Property GmbH Arylaminoalcohol-substituted 2,3-dihydroimidazo[1,2-c]quinolines
UA113280C2 (xx) * 2010-11-11 2017-01-10 АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ
CA2817312A1 (en) * 2010-11-11 2012-05-18 Bayer Intellectual Property Gmbh Alkoxy-substituted 2,3-dihydroimidazo[1,2-c]quinazolines

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004029055A1 (en) * 2002-09-30 2004-04-08 Bayer Pharmaceuticals Corporation Fused azole-pyrimidine derivatives
WO2008070150A1 (en) * 2006-12-05 2008-06-12 Bayer Schering Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2010034414A1 (en) * 2008-09-24 2010-04-01 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma

Also Published As

Publication number Publication date
MX2013005305A (es) 2013-06-13
GT201300121A (es) 2014-12-22
TW201305170A (zh) 2013-02-01
KR20140003436A (ko) 2014-01-09
AP2013006921A0 (en) 2013-06-30
US20150080374A1 (en) 2015-03-19
PE20140411A1 (es) 2014-04-13
ECSP13012618A (es) 2013-07-31
CN102906094A (zh) 2013-01-30
MY164730A (en) 2018-01-30
EP2638045A1 (en) 2013-09-18
SG190100A1 (en) 2013-07-31
CO6761350A2 (es) 2013-09-30
CR20130213A (es) 2013-07-01
JP2013542238A (ja) 2013-11-21
ZA201304244B (en) 2014-12-23
US20130317004A1 (en) 2013-11-28
NZ610018A (en) 2016-03-31
EP2638045B1 (en) 2022-08-31
DOP2013000105A (es) 2013-09-30
CU20130069A7 (es) 2013-09-27
EA024406B1 (ru) 2016-09-30
IL226066A0 (en) 2013-06-27
US8895549B2 (en) 2014-11-25
AU2011328192B2 (en) 2016-09-01
CL2013001295A1 (es) 2013-10-04
UA113280C2 (xx) 2017-01-10
CN102906094B (zh) 2016-06-22
EA201300556A1 (ru) 2013-10-30
UY33719A (es) 2012-06-29
CA2817317C (en) 2020-07-14
MA34655B1 (fr) 2013-11-02
CA2817317A1 (en) 2012-05-18
WO2012062748A1 (en) 2012-05-18
AU2011328192A1 (en) 2013-05-02
US9902727B2 (en) 2018-02-27
BR112013011634A2 (pt) 2018-12-11
JP6196156B2 (ja) 2017-09-13
HK1180685A1 (zh) 2013-10-25
AR083842A1 (es) 2013-03-27

Similar Documents

Publication Publication Date Title
AP3337A (en) Aminoalcohol substituted 2,3-dihydroimidazo[1,2-C]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
IL198273A0 (en) Substituted 2,3-dihydroimidazo[1,2-c] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
AP3709A (en) Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
EP2244721A4 (en) Sulfone substituted 2,3-dihydroimidazo ý1,2-c¨quinazoline derivatives useful for treating hyper-proliferative disorders and diseases with angiogenesis
ZA201209632B (en) Imidazopyridine derivatives, process for the preparation thereof and therapeutic use thereof
ZA201300100B (en) Indolizine derivatives,process for the preparation thereof and therapeutic use thereof
HK1168091A1 (en) Oxazine derivatives and their use in the treatment of neurological disorders
ZA201005201B (en) Azabicyclic carboxamide derivatives, preparation thereof and therapeutic use thereof
IL207078A0 (en) Azabicyclic carboxamide derivatives, preparation thereof and therapeutic use thereof
HK1171456A1 (en) 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl derivatives, methods for the production thereof and use thereof for treating diseases 17--17---49(10)--11-
AP3751A (en) Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
IL215286A0 (en) 9h-pyrrolo[2,3-b:5,4-c]dipridine azacarboline derivatives, preparation thereof, and therapeutic use thereof
ZA201307511B (en) Pyrido [2,3-b] pyrazine derivatives and their therapeutical uses
IL228555A0 (en) The history of thiani[3,2–d]pyrimidines and their use to treat cardiac arrhythmias